Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2020 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020

WALTHAM, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
February 28, 2020 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in Schizophrenia

WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
February 05, 2020 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

WALTHAM, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet...
January 06, 2020 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

WALTHAM, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet...
December 18, 2019 16:05 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder

MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpointsMIN-117 was generally well-tolerated with a safety profile comparable to placeboCompany to host conference call at...
November 14, 2019 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019

WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
November 04, 2019 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates

WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 28, 2019 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019

WALTHAM, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 01, 2019 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Update for Three Clinical Trials

WALTHAM, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
September 26, 2019 16:10 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET

WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right